Roivant Sciences (NASDAQ:ROIV) Insider Frank Torti Sells 1,400,000 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Frank Torti sold 1,400,000 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $27.42, for a total transaction of $38,388,000.00. Following the sale, the insider owned 13,736,547 shares in the company, valued at approximately $376,656,118.74. The trade was a 9.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Frank Torti also recently made the following trade(s):

• On Friday, February 20th, Frank Torti sold 1,012,610 shares of Roivant Sciences stock. The stock was sold at an average price of $27.15, for a total value of $27,492,361.50.
• On Monday, February 23rd, Frank Torti sold 587,390 shares of Roivant Sciences stock. The shares were sold at an average price of $27.51, for a total value of $16,159,098.90.

Roivant Sciences Price Performance

Shares of Roivant Sciences stock opened at $27.76 on Tuesday. The firm has a market cap of $19.87 billion, a price-to-earnings ratio of -23.73 and a beta of 1.22. The stock’s 50-day moving average is $23.44 and its 200-day moving average is $19.07. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $27.94.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ROIV. Leerink Partners raised their price target on shares of Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. The Goldman Sachs Group increased their target price on shares of Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, December 15th. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a research note on Saturday, February 7th. HC Wainwright boosted their price target on shares of Roivant Sciences from $26.00 to $33.00 and gave the stock a “buy” rating in a research report on Tuesday, February 10th. Finally, Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Roivant Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $28.69.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ROIV. Oregon Public Employees Retirement Fund increased its holdings in shares of Roivant Sciences by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock worth $1,891,000 after acquiring an additional 500 shares during the last quarter. Bank of Montreal Can lifted its stake in shares of Roivant Sciences by 1.3% during the 4th quarter. Bank of Montreal Can now owns 40,012 shares of the company’s stock worth $868,000 after buying an additional 516 shares during the last quarter. Bessemer Group Inc. boosted its holdings in shares of Roivant Sciences by 41.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after buying an additional 543 shares during the period. Allworth Financial LP boosted its holdings in shares of Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares during the period. Finally, Fifth Third Bancorp grew its stake in Roivant Sciences by 15.8% in the 4th quarter. Fifth Third Bancorp now owns 4,310 shares of the company’s stock valued at $94,000 after buying an additional 588 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.